GlobeNewswire by notified

HMNC Brain Health and Develco Pharma Partner to Initiate Ketamine Study Targeting Treatment-Resistant Depression (TRD)

Share

Phase II Proof-of-Concept to study TRD patients resistant to standard antidepressants

MUNICH, Germany, Aug. 24, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, will advance the development of an investigational oral prolonged- release formulation of ketamine targeting treatment-resistant depression (TRD) with a clinical phase-II-study that will commence in Q4 2021. HMNC and Swiss-based Develco Pharma have created a joint venture and formed the company Ketabon, which will initiate a Contract Research Organization (CRO)-led proof-of-concept study. The study will be managed by SCOPE, an internationally renowned CRO headquartered in Germany.

Dr. Hans Eriksson, HMNC Brain Health’s Chief Clinical Development Officer, noted: “TRD patients with insufficient response to standard antidepressants represent about 30 percent of all patients suffering from major depressive disorder. Within this group, ketamine has already achieved high response rates. The pharmacokinetic profile of our prolonged-release formulation could significantly improve the risk profile and patient convenience, by eliminating dissociative side effects compared to the currently applied therapies.”

“Our oral prolonged-release formulation of ketamine could sustainably transform the therapy of treatment-resistant depression,” adds Dr. Markus Zimmer, Co-CEO of Ketabon and Member of the Board at Develco Pharma. “On top of the targeted medical benefits, the compound has the potential to be administered outside the ambulatory setting, resulting in a potentially higher level of patient compliance and accessibility.”

Data from the Ketabon project trial is likely to be reported in Q1 2023. An investigator-initiated phase II proof-of-concept ketamine study is ongoing at the renowned Psychiatric University Clinic Zurich and should lead to first data as early as Q1, 2022.

AboutHMNCBrainHealth

HMNC Brain Health (HMNC Holding GmbH) is a biopharma company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

AbouttheKetabonProject

Within the Ketabon project, HMNC Brain Health, and Develco Pharma in Switzerland develop an oral prolonged-release (PR) formulation of ketamine for treatment resistant depression (TRD) without dissociative side effects, currently in investigator-initiated Phase-II. The pharmacokinetic profile of the prolonged-release formulation could significantly improve the risk profile and patient convenience, by eliminating dissociative side effects compared to the currently applied intravenous and intranasal therapies. As TRD patients with insufficient response to standard antidepressants represent about 30 percent of all patients suffering from major depressive disorder and ketamine shows high response rates, the project represents a huge market potential. Clinical development of oral prolonged-release ketamine could also be expanded into other indications such as social anxiety, aggression, or panic disorder in the future.

AboutSCOPE

SCOPE International is firmly positioned in the clinical research market as a customer-oriented contract research organization that has offices in 16 countries throughout Europe and USA. SCOPE International provides the complete range of clinical development and consulting services to the pharmaceutical, biotechnology and medical device industries, and is supported by long established partnerships in other geographies. As a full-service provider SCOPE International sets the highest standards for the quality of its cost-effective services while achieving industry leading benchmarks in operational performance and timelines.

Mediacontacts:

Alexander Schmidt, (Europe)
Telefon: +49 151 22 99 39 765
E-Mail: alexander.schmidt@gaulyadvisors.com

Anne Donohoe (U.S.)
212.896.1265
hmnc@kcsa.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fortuna files Form 40-F, Annual Report28.3.2024 22:00:00 CET | Press release

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that the Company has filed today its fiscal 2023 annual report on Form 40-F with the U.S. Securities and Exchange Commission (“SEC”). The Form 40-F, which includes the Company’s fiscal 2023 annual audited financial statements, management’s discussion and analysis, and annual information form, is available on the Company’s website and on the SEC´s website. Printed copies of the annual financial statements are available free of charge to Fortuna shareholders upon written request. About Fortuna Silver Mines Inc. Fortuna Silver Mines Inc. is a Canadian precious metals mining company with five operating mines in Argentina, Burkina Faso, Côte d'Ivoire, Mexico, and Peru. Sustainability is integral to all our operations and relationships. We produce gold and silver and generate shared value over the long-term for our stakeholders through efficient production, environmental p

Nokia Corporation: Repurchase of own shares on 28.03.202428.3.2024 21:30:00 CET | Press release

Nokia Corporation Stock Exchange Release 28 March 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 28.03.2024 Espoo, Finland – On 28 March 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL467,1243.29CEUX--BATE--AQEU--TQEX--Total467,1243.29 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 202328.3.2024 21:28:47 CET | Press release

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47)for the treatment of solid tumors BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023. “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “We are laser focused on executing the PRESent registrational studies for SerpinPC, a potential first-in-class subcutaneously administered therapy with a differentiated safety profile for individuals with he

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results28.3.2024 21:05:00 CET | Press release

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, “I’m pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin against the backdrop of significant cost cutting initiatives undertaken to align our operating structure with our strategic vision for growth. We believe that our rapid and flexible mRNA synthesis kits are game-changing and unlock tremendous value by providing customers control over their screening and d

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings28.3.2024 21:01:00 CET | Press release

Publication of annual report for financial year 2023Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders’ Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company. The annual report for the financial year 2023, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. Our annual 2023 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the

HiddenA line styled icon from Orion Icon Library.Eye